-
Mashup Score: 0Keytruda combination improves OS for HER2-positive advanced gastric cancer in phase III trial - The Cancer Letter - 15 hour(s) ago
The phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival for the first-line treatment of patients with human epidermal growth factor receptor 2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. To access this subscriber-only […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 15Over three years as CEO, Karen Knudsen led ACS through COVID—and reversed the charity’s long slump - The Cancer Letter - 16 hour(s) ago
Over the past three years, the American Cancer Society has recovered from the fundraising decline brought on by COVID-19 and has reversed the years-long fundraising slump in public support. This three-year financial performance has led the charity’s board to extend the employment contract for its CEO, Karen E. Knudsen. Public support for the charity has […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Citing need for “more conversations” on menthol, White House scuttles move to ban the flavor favored by Black smokers - The Cancer Letter - 18 hour(s) ago
The Biden administration has—for the second time—delayed the decision on a proposed FDA rule that would ban menthol cigarettes and all flavors in cigars. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0NCI Trials for May 2024 - The Cancer Letter - 18 hour(s) ago
The National Cancer Institute approved the following clinical research studies last month. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.Login […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 29Sana Karam to lead radiation oncology at Siteman - The Cancer Letter - 19 hour(s) ago
Sana D. Karam will lead radiation oncology at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, beginning Oct. 1. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0CHMP recommends approval of fruquintinib for previously-treated mCRC - The Cancer Letter - 21 hour(s) ago
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors-1, -2, and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer. To access this subscriber-only content please log in or renew your subscription.Looking for IP […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2USPSTF’s Wanda Nicholson: Final recommendation to start breast cancer screening at 40 will save 20% more lives - The Cancer Letter - 22 hour(s) ago
All women should start screening for breast cancer at age 40, with biennial screening continuing through age 74, the U.S. Preventive Services Task Force said in its final recommendation statement April 30. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login system is now automatic. If […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Miriam Merad named dean for Translational Research and Therapeutic Innovation at Mt. Sinai - The Cancer Letter - 2 day(s) ago
Miriam Merad was named dean for Translational Research and Therapeutic Innovation of the Icahn School of Medicine at Mount Sinai. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Canine cancers as models: We have barely tapped the full potential of comparative oncology - The Cancer Letter - 2 day(s) ago
In 2024, an estimated 6 million pet dogs will be diagnosed with cancer in the United States. As someone who has lost several family dogs to cancer, I know how heartbreaking this diagnosis will be for each of those dogs’ owners. To access this subscriber-only content please log in or renew your subscription.Looking for IP […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA issues additional draft guidance on eligibility criteria for cancer drug clinical trials - The Cancer Letter - 2 day(s) ago
FDA issued three draft guidance documents on eligibility criteria in cancer clinical trials to address performance status, washout periods and concomitant medications, and laboratory values. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet
Keytruda combination improves OS for HER2-positive advanced gastric cancer in phase III trial. https://t.co/2RM4tSRVim https://t.co/Bf7pcS3Czr